Next Generation Diabetes Therapy and Drug Delivery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas), By Indication (Type 1 diabetes, Type 2 diabetes), By End user (Diagnostic/Clinics, Intensive Care Units (ICUs), Home Healthcare), By Region & Competition, 2021-2031F
The Global Next Generation Diabetes Therapy and Drug Delivery Market is projected to expand from USD 23.86 Billion in 2025 to USD 36.31 Billion by 2031, reflecting a compound annual growth rate of 7.25%. This sector encompasses advanced pharmacological agents, including novel insulin analogs and glucagon-like peptide-1 receptor agonists, integrated with automated administration technologies such as patch pumps and continuous glucose monitors to enhance glycemic regulation. The primary factors driving this market include the urgent requirement for non-invasive treatment alternatives that boost patient compliance and the rapidly escalating global burden of metabolic conditions. As reported by the International Diabetes Federation in 2024, roughly 589 million adults globally were living with diabetes, generating substantial demand for these sophisticated therapeutic interventions.
However, a major obstacle hindering market progression is the prohibitive expense associated with these advanced biologics and devices, which restricts access in cost-conscious regions and creates significant reimbursement difficulties. This economic hurdle, coupled with rigorous regulatory standards for approving complex combination products, limits the pace at which these therapies become available to the broader patient population.
Market Driver
The rising global prevalence of diabetes and obesity-related comorbidities acts as a major catalyst accelerating the adoption of integrated delivery systems and advanced pharmacological interventions. This surge in metabolic disorders drives patient dependence on next-generation therapies, specifically dual GIP and GLP-1 receptor agonists, which deliver superior glycemic control and weight management compared to conventional insulin regimens. A direct correlation exists between increasing disease incidence and the commercial success of these novel biologics, as healthcare providers prioritize treatments that address both glucose regulation and weight reduction. Reflecting this high demand, Eli Lilly and Company reported in their Q2 2024 financial results that worldwide revenue for the therapy Mounjaro jumped to $3.09 billion in the second quarter alone, highlighting the role of disease burden in driving the uptake of innovative formulations.
Furthermore, rapid advancements in closed-loop and automated insulin delivery systems stimulate market growth by meeting the growing patient need for continuous, minimally invasive monitoring solutions. Technologies merging real-time data analytics with automated dosing alleviate the cognitive load on patients and lower hypoglycemia risks associated with manual injections. The proliferation of these sophisticated devices is crucial for managing the wider metabolic crisis, particularly given the World Health Organization?s 2024 report that over 1 billion people worldwide were living with obesity, creating a vast need for scalable therapeutic options. Consequently, manufacturers are seeing strong adoption; Abbott?s Third Quarter 2024 financial results indicated global sales of the FreeStyle Libre system reached $1.6 billion, driven by its ability to facilitate personalized care.
Market Challenge
The high cost associated with advanced diabetes biologics and devices represents a significant barrier that directly hampers the growth of the Global Next Generation Diabetes Therapy and Drug Delivery Market. Although automated delivery systems and novel insulin analogs provide superior glycemic control, their elevated price points make them inaccessible to a large portion of the global population, especially in developing regions where out-of-pocket payment is common. This economic disparity limits the addressable market primarily to affluent demographics or those with extensive insurance coverage, making it difficult for manufacturers to scale adoption rates outside of developed markets.
Moreover, this financial burden leads to intensified scrutiny from insurance providers and healthcare payers, resulting in strict reimbursement criteria that delay market penetration. The immense scale of existing costs makes payers reluctant to approve expensive new therapies. According to the International Diabetes Federation, diabetes accounted for an estimated USD 1.015 trillion in global health expenditure in 2024. This profound financial strain compels healthcare systems to prioritize cost containment, thereby restricting the widespread funding and uptake of premium therapeutic technologies.
Market Trends
The market is witnessing a distinct shift toward miniaturized and tubeless wearable patch pump technologies, which are fundamentally transforming insulin delivery mechanisms. In contrast to traditional durable pumps that rely on tubing, these discreet, waterproof devices adhere directly to the skin, offering patients increased freedom and minimizing the stigma often associated with visible medical equipment. This specific form factor is particularly appealing to younger demographics and individuals with active lifestyles who previously avoided pump therapy due to the physical limitations of tubed devices. The commercial viability of this trend is evident in Insulet Corporation?s Third Quarter 2024 financial results, where revenue hit $543.9 million, largely driven by high demand for their tubeless automated insulin delivery platform.
Concurrently, there is a rapid expansion of open-architecture diabetes ecosystems and device interoperability, facilitating the seamless integration of components from various manufacturers. This trend moves away from proprietary, single-brand systems, allowing patients to pair their preferred insulin pumps with different continuous glucose monitoring sensors to create customized management solutions. This flexibility improves user experience and promotes broader adoption of automated therapy by eliminating hardware compatibility barriers that formerly restricted patient choice. Reflecting the financial impact of this cross-compatibility strategy, Tandem Diabetes Care reported in their Third Quarter 2024 financial results that worldwide sales totaled $243.5 million, bolstered by the integration of their pump platforms with multiple sensor technologies.
Key Market Players
In this report, the Global Next Generation Diabetes Therapy and Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Next Generation Diabetes Therapy and Drug Delivery Market.
Available Customizations:
Global Next Generation Diabetes Therapy and Drug Delivery Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
However, a major obstacle hindering market progression is the prohibitive expense associated with these advanced biologics and devices, which restricts access in cost-conscious regions and creates significant reimbursement difficulties. This economic hurdle, coupled with rigorous regulatory standards for approving complex combination products, limits the pace at which these therapies become available to the broader patient population.
Market Driver
The rising global prevalence of diabetes and obesity-related comorbidities acts as a major catalyst accelerating the adoption of integrated delivery systems and advanced pharmacological interventions. This surge in metabolic disorders drives patient dependence on next-generation therapies, specifically dual GIP and GLP-1 receptor agonists, which deliver superior glycemic control and weight management compared to conventional insulin regimens. A direct correlation exists between increasing disease incidence and the commercial success of these novel biologics, as healthcare providers prioritize treatments that address both glucose regulation and weight reduction. Reflecting this high demand, Eli Lilly and Company reported in their Q2 2024 financial results that worldwide revenue for the therapy Mounjaro jumped to $3.09 billion in the second quarter alone, highlighting the role of disease burden in driving the uptake of innovative formulations.
Furthermore, rapid advancements in closed-loop and automated insulin delivery systems stimulate market growth by meeting the growing patient need for continuous, minimally invasive monitoring solutions. Technologies merging real-time data analytics with automated dosing alleviate the cognitive load on patients and lower hypoglycemia risks associated with manual injections. The proliferation of these sophisticated devices is crucial for managing the wider metabolic crisis, particularly given the World Health Organization?s 2024 report that over 1 billion people worldwide were living with obesity, creating a vast need for scalable therapeutic options. Consequently, manufacturers are seeing strong adoption; Abbott?s Third Quarter 2024 financial results indicated global sales of the FreeStyle Libre system reached $1.6 billion, driven by its ability to facilitate personalized care.
Market Challenge
The high cost associated with advanced diabetes biologics and devices represents a significant barrier that directly hampers the growth of the Global Next Generation Diabetes Therapy and Drug Delivery Market. Although automated delivery systems and novel insulin analogs provide superior glycemic control, their elevated price points make them inaccessible to a large portion of the global population, especially in developing regions where out-of-pocket payment is common. This economic disparity limits the addressable market primarily to affluent demographics or those with extensive insurance coverage, making it difficult for manufacturers to scale adoption rates outside of developed markets.
Moreover, this financial burden leads to intensified scrutiny from insurance providers and healthcare payers, resulting in strict reimbursement criteria that delay market penetration. The immense scale of existing costs makes payers reluctant to approve expensive new therapies. According to the International Diabetes Federation, diabetes accounted for an estimated USD 1.015 trillion in global health expenditure in 2024. This profound financial strain compels healthcare systems to prioritize cost containment, thereby restricting the widespread funding and uptake of premium therapeutic technologies.
Market Trends
The market is witnessing a distinct shift toward miniaturized and tubeless wearable patch pump technologies, which are fundamentally transforming insulin delivery mechanisms. In contrast to traditional durable pumps that rely on tubing, these discreet, waterproof devices adhere directly to the skin, offering patients increased freedom and minimizing the stigma often associated with visible medical equipment. This specific form factor is particularly appealing to younger demographics and individuals with active lifestyles who previously avoided pump therapy due to the physical limitations of tubed devices. The commercial viability of this trend is evident in Insulet Corporation?s Third Quarter 2024 financial results, where revenue hit $543.9 million, largely driven by high demand for their tubeless automated insulin delivery platform.
Concurrently, there is a rapid expansion of open-architecture diabetes ecosystems and device interoperability, facilitating the seamless integration of components from various manufacturers. This trend moves away from proprietary, single-brand systems, allowing patients to pair their preferred insulin pumps with different continuous glucose monitoring sensors to create customized management solutions. This flexibility improves user experience and promotes broader adoption of automated therapy by eliminating hardware compatibility barriers that formerly restricted patient choice. Reflecting the financial impact of this cross-compatibility strategy, Tandem Diabetes Care reported in their Third Quarter 2024 financial results that worldwide sales totaled $243.5 million, bolstered by the integration of their pump platforms with multiple sensor technologies.
Key Market Players
- Abbott Laboratories
- Dexcom Inc.
- Eli Lilly and Company
- Enteris BioPharma Inc.
- GlySens Incorporated
- MannKind Corporation
- Medtronic plc
- Sanofi S.A.
- Senseonics, Holdings
In this report, the Global Next Generation Diabetes Therapy and Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Next Generation Diabetes Therapy and Drug Delivery Market, By Product Type
- Inhalable Insulin
- Oral Insulin
- Insulin Patches
- CGM Systems
- Artificial Pancreas
- Next Generation Diabetes Therapy and Drug Delivery Market, By Indication
- Type 1 diabetes
- Type 2 diabetes
- Next Generation Diabetes Therapy and Drug Delivery Market, By End user
- Diagnostic/Clinics
- Intensive Care Units (ICUs)
- Home Healthcare
- Next Generation Diabetes Therapy and Drug Delivery Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Next Generation Diabetes Therapy and Drug Delivery Market.
Available Customizations:
Global Next Generation Diabetes Therapy and Drug Delivery Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas)
5.2.2. By Indication (Type 1 diabetes, Type 2 diabetes)
5.2.3. By End user (Diagnostic/Clinics, Intensive Care Units (ICUs), Home Healthcare)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Indication
6.2.3. By End user
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Next Generation Diabetes Therapy and Drug Delivery Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product Type
6.3.1.2.2. By Indication
6.3.1.2.3. By End user
6.3.2. Canada Next Generation Diabetes Therapy and Drug Delivery Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product Type
6.3.2.2.2. By Indication
6.3.2.2.3. By End user
6.3.3. Mexico Next Generation Diabetes Therapy and Drug Delivery Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product Type
6.3.3.2.2. By Indication
6.3.3.2.3. By End user
7. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Indication
7.2.3. By End user
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Next Generation Diabetes Therapy and Drug Delivery Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product Type
7.3.1.2.2. By Indication
7.3.1.2.3. By End user
7.3.2. France Next Generation Diabetes Therapy and Drug Delivery Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product Type
7.3.2.2.2. By Indication
7.3.2.2.3. By End user
7.3.3. United Kingdom Next Generation Diabetes Therapy and Drug Delivery Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product Type
7.3.3.2.2. By Indication
7.3.3.2.3. By End user
7.3.4. Italy Next Generation Diabetes Therapy and Drug Delivery Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product Type
7.3.4.2.2. By Indication
7.3.4.2.3. By End user
7.3.5. Spain Next Generation Diabetes Therapy and Drug Delivery Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product Type
7.3.5.2.2. By Indication
7.3.5.2.3. By End user
8. ASIA PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Indication
8.2.3. By End user
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Next Generation Diabetes Therapy and Drug Delivery Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product Type
8.3.1.2.2. By Indication
8.3.1.2.3. By End user
8.3.2. India Next Generation Diabetes Therapy and Drug Delivery Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product Type
8.3.2.2.2. By Indication
8.3.2.2.3. By End user
8.3.3. Japan Next Generation Diabetes Therapy and Drug Delivery Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product Type
8.3.3.2.2. By Indication
8.3.3.2.3. By End user
8.3.4. South Korea Next Generation Diabetes Therapy and Drug Delivery Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product Type
8.3.4.2.2. By Indication
8.3.4.2.3. By End user
8.3.5. Australia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product Type
8.3.5.2.2. By Indication
8.3.5.2.3. By End user
9. MIDDLE EAST & AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Indication
9.2.3. By End user
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product Type
9.3.1.2.2. By Indication
9.3.1.2.3. By End user
9.3.2. UAE Next Generation Diabetes Therapy and Drug Delivery Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product Type
9.3.2.2.2. By Indication
9.3.2.2.3. By End user
9.3.3. South Africa Next Generation Diabetes Therapy and Drug Delivery Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product Type
9.3.3.2.2. By Indication
9.3.3.2.3. By End user
10. SOUTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Indication
10.2.3. By End user
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Next Generation Diabetes Therapy and Drug Delivery Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product Type
10.3.1.2.2. By Indication
10.3.1.2.3. By End user
10.3.2. Colombia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product Type
10.3.2.2.2. By Indication
10.3.2.2.3. By End user
10.3.3. Argentina Next Generation Diabetes Therapy and Drug Delivery Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product Type
10.3.3.2.2. By Indication
10.3.3.2.3. By End user
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Abbott Laboratories
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Dexcom Inc.
15.3. Eli Lilly and Company
15.4. Enteris BioPharma Inc.
15.5. GlySens Incorporated
15.6. MannKind Corporation
15.7. Medtronic plc
15.8. Sanofi S.A.
15.9. Senseonics, Holdings
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas)
5.2.2. By Indication (Type 1 diabetes, Type 2 diabetes)
5.2.3. By End user (Diagnostic/Clinics, Intensive Care Units (ICUs), Home Healthcare)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Indication
6.2.3. By End user
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Next Generation Diabetes Therapy and Drug Delivery Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product Type
6.3.1.2.2. By Indication
6.3.1.2.3. By End user
6.3.2. Canada Next Generation Diabetes Therapy and Drug Delivery Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product Type
6.3.2.2.2. By Indication
6.3.2.2.3. By End user
6.3.3. Mexico Next Generation Diabetes Therapy and Drug Delivery Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product Type
6.3.3.2.2. By Indication
6.3.3.2.3. By End user
7. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Indication
7.2.3. By End user
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Next Generation Diabetes Therapy and Drug Delivery Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product Type
7.3.1.2.2. By Indication
7.3.1.2.3. By End user
7.3.2. France Next Generation Diabetes Therapy and Drug Delivery Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product Type
7.3.2.2.2. By Indication
7.3.2.2.3. By End user
7.3.3. United Kingdom Next Generation Diabetes Therapy and Drug Delivery Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product Type
7.3.3.2.2. By Indication
7.3.3.2.3. By End user
7.3.4. Italy Next Generation Diabetes Therapy and Drug Delivery Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product Type
7.3.4.2.2. By Indication
7.3.4.2.3. By End user
7.3.5. Spain Next Generation Diabetes Therapy and Drug Delivery Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product Type
7.3.5.2.2. By Indication
7.3.5.2.3. By End user
8. ASIA PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Indication
8.2.3. By End user
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Next Generation Diabetes Therapy and Drug Delivery Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product Type
8.3.1.2.2. By Indication
8.3.1.2.3. By End user
8.3.2. India Next Generation Diabetes Therapy and Drug Delivery Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product Type
8.3.2.2.2. By Indication
8.3.2.2.3. By End user
8.3.3. Japan Next Generation Diabetes Therapy and Drug Delivery Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product Type
8.3.3.2.2. By Indication
8.3.3.2.3. By End user
8.3.4. South Korea Next Generation Diabetes Therapy and Drug Delivery Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product Type
8.3.4.2.2. By Indication
8.3.4.2.3. By End user
8.3.5. Australia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product Type
8.3.5.2.2. By Indication
8.3.5.2.3. By End user
9. MIDDLE EAST & AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Indication
9.2.3. By End user
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product Type
9.3.1.2.2. By Indication
9.3.1.2.3. By End user
9.3.2. UAE Next Generation Diabetes Therapy and Drug Delivery Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product Type
9.3.2.2.2. By Indication
9.3.2.2.3. By End user
9.3.3. South Africa Next Generation Diabetes Therapy and Drug Delivery Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product Type
9.3.3.2.2. By Indication
9.3.3.2.3. By End user
10. SOUTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Indication
10.2.3. By End user
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Next Generation Diabetes Therapy and Drug Delivery Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product Type
10.3.1.2.2. By Indication
10.3.1.2.3. By End user
10.3.2. Colombia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product Type
10.3.2.2.2. By Indication
10.3.2.2.3. By End user
10.3.3. Argentina Next Generation Diabetes Therapy and Drug Delivery Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product Type
10.3.3.2.2. By Indication
10.3.3.2.3. By End user
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Abbott Laboratories
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Dexcom Inc.
15.3. Eli Lilly and Company
15.4. Enteris BioPharma Inc.
15.5. GlySens Incorporated
15.6. MannKind Corporation
15.7. Medtronic plc
15.8. Sanofi S.A.
15.9. Senseonics, Holdings
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
